Dec 2 (Reuters) – Novavax Inc said on Thursday it could begin commercial manufacturing of a COVID-19 vaccine tailored for the Omicron coronavirus variant in January next year, while it tests whether or not its current vaccine works against the variant.
Laboratory data expected in the coming weeks will show whether antibodies from individuals who have previously received Novavax’s COVID-19 shot can neutralize the variant, according to the company.
Novavax also said it has started developing an Omicron-specific spike protein antigen and will begin laboratory tests of a new vaccine to target the variant in a few weeks.
The Omicron coronavirus variant has shaken up markets and caused global alarm over concerns about whether it could evade protection provided by widely used vaccines and prolong the public health crisis.
Other vaccine makers including Moderna and Pfizer have also begun working on Omicron-tailored COVID-19 shots.
Novavax’s COVID-19 vaccine received its first emergency use approval in Indonesia in early November followed by the Philippines.
(Reporting by Amruta Khandekar; Editing by Shounak Dasgupta)
With Texas’ new congressional map on the verge of full passage, local elected Republican officials…
U.S. Rep. Chip Roy, R-Austin, announced a run for Texas attorney general Thursday, joining a…
Starting September 1, every Texas public school classroom will be required to display a poster…
The Texas State Capitol was evacuated Tuesday evening following a reported threat made on social…
President Donald Trump has renewed his push to abolish mail-in voting, promising to sign an…
The battle over congressional maps intensified this week as Texas Republicans advanced a redistricting bill…
This website uses cookies.